The lancet oncology
-
The lancet oncology · Apr 2014
Multicenter Study Clinical TrialVemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival (PFS), and overall survival in patients with metastatic melanoma that has a BRAF(V600) mutation. We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options. ⋯ F Hoffmann-La Roche.
-
The lancet oncology · Apr 2014
Randomized Controlled Trial Comparative Study4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.
Follicular lymphoma has been shown to be highly radiosensitive with responses to doses as low as 4 Gy in two fractions. This trial was designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with 24 Gy in 12 fractions ⋯ Cancer Research UK.
-
The lancet oncology · Apr 2014
Multicenter StudyClinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data. ⋯ Janssen Diagnostics, the Nuovo-Soldati foundation for cancer research.
-
The lancet oncology · Apr 2014
Randomized Controlled Trial Comparative StudyRituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Patients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchful waiting until disease progression. We assessed whether rituximab use could delay the need for chemotherapy or radiotherapy compared with watchful waiting and the effect of this strategy on quality of life (QoL). ⋯ Cancer Research UK, Lymphoma Research Trust, Lymphoma Association, and Roche.
-
Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. ⋯ This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.